MLTX NEWS: MoonLake Immunotherapeutics Sued for Securities Fraud after Stock Plummets 90% -- Investors Notified to Contact BFA Law by December 15 Deadline

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, particularly related to the company's clinical data and the performance of its investigational drug sonelokimab [1][2][5]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612 [2]. - Investors have until December 15, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [3]. - The company conducted Phase 3 VELA trials for sonelokimab, aimed at treating moderate to severe hidradenitis suppurativa [3]. Group 3: Clinical Data and Claims - MoonLake claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated superior clinical responses for patients and differentiation from competitors [4]. - Allegations suggest that the clinical data and the Nanobody structure of sonelokimab did not provide a superior clinical benefit, raising concerns about the drug's regulatory approval and commercial viability [5]. Group 4: Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted by $55.75 per share, nearly 90%, from $61.99 on September 26, 2025, to $6.24 on September 29, 2025 [6].